THERAFLU WARMING RELIEF COLD AND CHEST CONGESTION OTC
Generic Name and Formulations:
Acetaminophen 325mg, guaifenesin 200mg, phenylephrine HCl 5mg; per 15mL; liq; contains potassium 5mg/15mL, sodium 9mg/15mL; orange flavor.
Novartis Consumer Health
Indications for THERAFLU WARMING RELIEF COLD AND CHEST CONGESTION:
Minor aches and pains. Headache. Fever. Nasal and sinus congestion. Chest congestion.
30mL every 4 hours. Max 180mL/24hrs.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Liver disease. Heart disease. Hypertension. Thyroid disease. Diabetes. COPD. Asthma. GI or GU obstruction. Pregnancy. Nursing mothers.
Analgesic + expectorant + sympathomimetic.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day; avoid. β-blockers increase pressor effect of sympathomimetics. Antagonizes antihypertensives.
Nervousness, dizziness, insomnia; hepatotoxicity (overdosage).
Endocrinology Advisor Articles
- Cushing Syndrome Results in Poor Quality of Life Even After Remission
- DPP-4 Inhibitors and Incidence of Rheumatoid Arthritis in Type 2 Diabetes
- Cost-Benefit Analysis of Insulin Analogs in Type 2 Diabetes
- Low Predictive Power of Biomarkers for Estimated Glomerular Filtration Rate Decline
- Predictors of Weight Loss in Postpartum Women With Gestational Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Link Between Gestational Diabetes and Risk for CVD and Diabetes in Hispanic/Latina Population
- Clinical Characteristics Altering Risks and Benefits of Sulfonylureas and Thiazolidinedione Therapy in T2D
- 6 Factors Related to Inclusion in Health Care Workplace Identified
- Weight Gain After Quitting Smoking May Increase Risk for T2D